At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
IMSA101 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies
In Brief
A Phase 2 clinical trial evaluating IMSA101, Immune checkpoint inhibitor (ICI), and 1 other intervention for Solid Tumor, Adult. Completed, enrolled 40 participants across 6 sites.
Detailed Summary
Open-label, dose escalation (Phase I) and dose expansion (Phase IIA) study of patients receiving intra-tumoral IMSA101 alone or in combination with an immune checkpoint inhibitor (ICI) (Phase I and II)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Adult
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartSep 2019
Primary CompletionSep 2023
TodayJul 2026
First PostedJul 15, 2019
Enrollment StartSep 23, 2019
Primary CompletionSep 15, 2023
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 7.0 years ago
Interventions
IMSA101drug
IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.
Immune checkpoint inhibitor (ICI)drug
Administered according to product label
Immuno-oncology (IO) therapydrug
Administered according to product label